Merck & Co. Inc., of Kenilworth, N.J., said it will be stopping protocol 019, also known as the APECS study, a phase III trial evaluating verubecestat (MK-8931), a small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer's disease.